By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVBRESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl

SAN DIEGO, March 22, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results.

SAN DIEGO, March 13, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place

SAN DIEGO, March 12, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.

SAN DIEGO, March 04, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has commenced a first in human Phase 1 clinical study (RVL-HV02) to evaluate escalating doses of intravenously administered Gemini. The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of a

SAN DIEGO, February 13, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, as part of a limited number of accepted abstract authors, the company was invited to give an oral presentation of new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) at The 29th International Conference on Advances in Critical Care Nephrology taking place in San Diego from March 12-15, 2024. Gemini is the C

SAN DIEGO, February 05, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing on February 5, 2024 of its previously announced public offering of 128,470 shares of its common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its

SAN DIEGO, February 01, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the pricing of a public offering of 1,365,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of $4.53 per share and associate

SAN DIEGO, January 30, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024). Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl